Reproductive history and risk of type 2 diabetes mellitus in postmenopausal women: Findings from the Women's Health Initiative

Menopause

Volumn 24, Issue 1, 2017, Pages 64-72

  LeBlanc, Erin S ^a   Kapphahn, Kristopher ^b   Hedlin, Haley ^b   Desai, Manisha ^b   Parikh, Nisha I ^c   Liu, Simin ^d   Parker, Donna R ^e   Anderson, Matthew ^f   Aroda, Vanita ^g   Sullivan, Shannon ^g   Woods, Nancy F ^h   Waring, Molly E ⁱ   Lewis, Cora E ^j   Stefanick, Marcia ^b  

^a CENTER FOR HEALTH RESEARCH   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BROWN UNIVERSITY   (United States)

^e MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g WASHINGTON HOSPITAL CENTER   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^j University of Alabama at Birmingham   (United States)

more..

Author keywords

Cycle regularity; Diabetes; Menarche; Menopause; Reproductive risk duration

Indexed keywords

ESTROGEN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DISEASE DURATION; FEMALE; HUMAN; MENARCHE; MENSTRUAL CYCLE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COUNSELING; POSTMENOPAUSE; PROSPECTIVE STUDY; QUESTIONNAIRE; REPRODUCTIVE HISTORY; RISK FACTOR; SELF REPORT; SENSITIVITY ANALYSIS; WOMEN'S HEALTH; INCIDENCE; MENSTRUATION; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; TIME FACTOR;

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INCIDENCE; MENARCHE; MENSTRUATION; MIDDLE AGED; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REPRODUCTIVE HISTORY; RISK FACTORS; SELF REPORT; TIME FACTORS; WOMEN'S HEALTH;

EID: 84980044736     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0000000000000714     Document Type: Article

References (41)

1. Cignarella A, Bolego C. Mechanisms of estrogen protection in diabetes and metabolic disease. Horm Mol Biol Clin Investig 2011;4: 575-580.
2. Godsland IF. Oestrogens and insulin secretion. Diabetologia 2005;48: 2213-2220.
3. Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 2004;47:1175-1187.
4. Pentti K, Tuppurainen MT, Honkanen R, et al. Hormone therapy protects from diabetes: the Kuopio osteoporosis risk factor and prevention study. Eur J Endocrinol 2009;160:979-983.
5. Rossi R, Origliani G, Modena MG. Transdermal 17-beta-estradiol and risk of developing type 2 diabetes in a population of healthy, nonobese postmenopausal women. Diabetes Care 2004;27:645-649.
6. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and metaanalysis. JAMA 2006;295:1288-1299.
7. He C, Zhang C, Hunter DJ, et al. Age at menarche and risk of type 2 diabetes: results from 2 large prospective cohort studies. Am J Epidemiol 2010;171:334-344.
8. Lakshman R, Forouhi N, Luben R, et al. Association between age at menarche and risk of diabetes in adults: results from the EPIC-Norfolk cohort study. Diabetologia 2008;51:781-786.
9. Stockl D, Doring A, Peters A, et al. Age at menarche is associated with prediabetes and diabetes in women (aged 32-81 years) from the general population: the KORA F4 Study. Diabetologia 2012;55:681-688.
10. Dreyfus JG, Lutsey PL, Huxley R, et al. Age at menarche and risk of type 2 diabetes among African-American and white women in the Atherosclerosis Risk in Communities (ARIC) study. Diabetologia 2012; 55:2371-2380.
11. Elks CE, Ong KK, Scott RA, et al. Age at menarche and type 2 diabetes risk: the EPIC-InterAct study. Diabetes Care 2013;36:3526-3534.
12. Qiu C, Chen H, Wen J, et al. Associations between age at menarche and menopause with cardiovascular disease, diabetes, and osteoporosis in Chinese women. J Clin Endocrinol Metab 2013;98:1612-1621.
13. Heianza Y, Arase Y, Kodama S, et al. Effect of postmenopausal status and age at menopause on type 2 diabetes and prediabetes in Japanese individuals: Toranomon Hospital Health Management Center Study 17 (TOPICS 17). Diabetes Care 2013;36:4007-4014.
14. Kritz-Silverstein D, Barrett-Connor E, Wingard DL. Hysterectomy, oophorectomy, and heart disease risk factors in older women. Am J Public Health 1997;87:676-680.
15. Pirimoglu ZM, Arslan C, Buyukbayrak EE, et al. Glucose tolerance of premenopausal women after menopause due to surgical removal of ovaries. Climacteric 2011;14:453-457.
16. Brand JS, van der Schouw YT, Onland-Moret NC, et al. Age at menopause, reproductive life span, and type 2 diabetes risk: results from the EPIC-InterAct study. Diabetes Care 2013;36:1012-1019.
17. Monterrosa-Castro A, Blumel JE, Portela-Buelvas K, et al. Type II diabetes mellitus and menopause: amultinational study. Climacteric 2013;16:663-672.
18. Di Donato P, Giulini NA, Bacchi Modena A, et al. Risk factors for type 2 diabetes in women attending menopause clinics in Italy: a cross-sectional study. Climacteric 2005;8:287-293.
19. Luborsky JL, Meyer P, Sowers MF, Gold EB, Santoro N. Premature menopause in a multi-ethnic population study of the menopause transition. Hum Reprod 2003;18:199-206.
20. Kim C, Edelstein SL, Crandall JP, et al. Menopause and risk of diabetes in the Diabetes Prevention Program. Menopause 2011;18:857-868.
21. Dishi M, Enquobahrie DA, Abetew DF, Qiu C, Rudra CB, Williams MA. Age at menarche, menstrual cycle characteristics and risk of gestational diabetes. Diabetes Res Clin Pract 2011;93:437-442.
22. Brower M, Brennan K, Pall M, Azziz R. The severity of menstrual dysfunction as a predictor of insulin resistance in PCOS. J Clin Endocrinol Metab 2013;98:E1967-E1971.
23. Morrison JA, Glueck CJ, Daniels S, Wang P, Stroop D. Ramifications of adolescent menstrual cycles >/=42 days in young adults. Fertil Steril 2011;96:236-240.
24. Solomon CG, Hu FB, Dunaif A, et al. Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. JAMA 2001;286: 2421-2426.
25. Anderson GL, Manson J, Wallace R, et al. Implementation of theWomen's Health Initiative study design. Ann Epidemiol 2003;13(9 suppl):S5-S17.
26. Hays J, Hunt JR, Hubbell FA, et al. The Women's Health Initiative recruitment methods and results. Ann Epidemiol 2003;13(9 suppl):S18-S77.
27. Margolis KL, Lihong Q, Brzyski R, et al. Validity of diabetes self-reports in the Women's Health Initiative: comparison with medication inventories and fasting glucose measurements. Clin Trials 2008;5:240-247.
28. Weinstein M, Gorrindo T, Riley A, et al. Timing of menopause and patterns of menstrual bleeding. Am J Epidemiol 2003;158:782-791.
29. Yermachenko A, Dvornyk V. Nongenetic determinants of age at menarche: a systematic review. Biomed Res Int 2014;2014:371583.
30. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas 1992;14:103-115.
31. Beckles GL, Chou CF. Diabetes-United States, 2006 and 2010. MMWR Surveill Summ 2013;62(suppl 3):99-104.
32. Karim R, Stanczyk FZ, Brinton RD, Rettberg J, Hodis HN, Mack WJ. Association of endogenous sex hormones with adipokines and ghrelin in postmenopausal women. J Clin Endocrinol Metab 2015;100:508-515.
33. Mantzoros CS, Li T, Manson JE, Meigs JB, Hu FB. Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. J Clin Endocrinol Metab 2005;90:4542-4548.
34. Li S, Shin HJ,Ding EL, van DamRM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA2009;302:179-188.
35. Kalyani RR, Franco M, Dobs AS, et al. The association of endogenous sex hormones, adiposity, and insulin resistance with incident diabetes in postmenopausal women. J Clin Endocrinol Metab 2009;94:4127-4135.
36. Zhang Y, Howard BV, Cowan LD, et al. The effect of estrogen use on levels of glucose and insulin and the risk of type 2 diabetes in american Indian postmenopausal women: the strong heart study. Diabetes Care 2002;25:500-504.
37. Espeland MA, Hogan PE, Fineberg SE, et al. Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Diabetes Care 1998;21:1589-1595.
38. Farnett L, Mulrow CD, Linn WD, Lucey CR, Tuley MR. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? JAMA 1991;265:489-495.
39. O'Keefe JH, Bybee KA, Lavie CJ. Alcohol and cardiovascular health: the razor-sharp double-edged sword. J Am Coll Cardiol 2007;50:1009-1014.
40. Dasgupta D, Pal B, Ray S. Factors that discriminate age at menopause: A study of Bengali Hindu women of West Bengal. Am J Hum Biol 2015;27:710-715.
41. Dunaif A. Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus. Am J Med 1995;98:S33-S39.